failure (CHF), depression, osteoarthritis (OA), or diabetes. Cohorts (not mutually exclusive) were descriptively evaluated for observed self-reported QOL (SF-36v2) and work productivity and activity impairment (WPAI) assessments. Assessments were scored such that lower SF- 36v2 Mental Component Summary (MCS) and Physical Component Summary (PCS) scores corresponded to lower QOL while higher WPAI scores represented higher levels of impair- ment and work time missed. Results: Among the 71,157 NHWS total respondents, 0.9% reported an HCV diagnosis, 1.3% CHF, 2.8% MI, 5.0% COPD, 10.9% Diabetes, 14.9% Depression, and 17.3% OA. Among these 7 cohorts, the HCV cohort was the second youngest with a mean age of 54 years and had the second highest proportion of male respondents (69.8%). The HCV cohort was observed to have the second lowest average MCS scores (44.6) among the seven cohorts while having mean PCS scores (43.7) that were numerically third highest (Table 1.). Full-time employment was reported by 25.0% of the HCV group, 17.2% COPD, 28.9% Depression, 14.7% MI, 20.2% OA, 11.4% HF, and 24.4% Diabetes. Numerically, the HCV cohort had the second highest reported overall work impairment scores (29.5%) among the seven conditions and was ranked between cohorts for mean total activity impairment scores (39.8%). Conclusions: Results provide further insight into QOL and productivity as reported by a population of US survey respondents with HCV. Although one-fourth of survey respondents with HCV reported full-time employment, these same individuals reported productivity losses in the forms of absenteeism and presenteeism. Further evaluation of the impact of comorbidity burden and HCV treatment on these patient outcomes is warranted. Table 1. Cohort Mean Scores * Among respondents employed full-time 1. % impairment while working; 2. % work time missed; 3. % overall work impairment; 4. % activity impairment Su1030 Genetic Variation in Vitamin D Pathway DHCR7 Gene Predicts Poor Response to Pegylated Interferon-Alfa Based Therapy in Asian Chronic Hepatitis C Genotype 1-Infected Patients Kessarin Thanapirom, Sirinporn Suksawatamnuay, Wattana Sukeepaisarnjaroen, Pisit Tangkijvanich, Panarat Thaimai, Warattaya Sukkharin, Srunthron Akkarathamrongsin, Yong Poovorawan, Pinit Kullavanijaya, Piyawat Komolmit Background and aims: Patients with chronic hepatitis C (CHC) infection have high prevalence of vitamin D deficiency. Recent studies showed vitamin D deficiency was linked to more severe liver fibrosis and low treatment response rate in patients with chronic hepatitis C virus (HCV) infection. Vitamin D supplementation has been shown to improve the efficacy of combination therapy with pegylated-interferon and ribavirin. From genome-wide studies, several genetic variants affect serum 25-hydroxyvitamin D level. We aimed to determine the association of the common genetic polymorphism of vitamin D pathway gene and outcome of treatment with interferon-based therapy in patients with CHC infection. Methods: Overall 568 Asian patients with CHC infection treated with pegylated interferon-alfa based regimen were genotyped for rs12785878 G>T, near dehydrocholesterol reductase, DHCR7; rs12794714 C>T, at CYP2R1; and rs7041 G>T, at vitamin D binding protein, GC. Predictors of sustained virologic response (SVR: undetected HCV RNA at 24 weeks after discontinuation of therapy) were identified using multivariate analysis. Results: Of these, SVR was achieved by 60% of patients (51% in HCV genotype1 and 66% in HCV non-genotype 1). In CHC genotype 1-infected patients (44.8%), only the variant rs12785878 in the DHCR7 locus was significantly associated with SVR. Patients who had non-GG genotype had higher rate of SVR than GG genotype (59% vs 40%, p = 0.02), but in HCV non-genotype 1-infected patients, SVR rate was not different among the two groups (60% and 59% for non-GG and GG genotype, p=0.90) (Figure1). By multivariate analysis, poor treatment outcome in genotype-1 infected patients was independently associated with DHCR7 GG genotype (OR= 2.8, 95% CI = 1.08-7.35, p = 0.03), pre-treatment HCV RNA >= 400,000 IU/ml (OR= 3.0, 95% CI= 1.05-9.14, p = 0.04) and fibrosis stage2-4 (OR= 4.9, 95% CI = 1.94-12.39, p = 0.01). In addition, DHCR7 rs12794714 polymorphism was associated with end of treatment virologic response but not with rapid and early virologic responses. The polymorphism of CYP2R1 rs12794714 and GC rs7041 were not associated with treatment outcome even in HCV genotype 1 or non-genotype 1 infection. Conclusions: This study suggested that in Asian population, the GG genotype of DHCR7 gene was found to be independent predictor of poor treatment outcome with peg-interferon based therapy in patients with CHC genotype 1 infection. The use of DHCR7 polymorphism as a predictive tool may have an impact on treatment strategies for genotype 1 CHC infection, particularly in the emerging era with direct-acting antiviral therapy. S-967 AASLD Abstracts Figure 1: Genetic variations of vitamin D pathway related DHCR7 genes and treatment response (SVR) based on pegylated interferon/ribavirin therapy among patients with chronic hepatitis C genotype 1 and non-genotype 1 Su1031 Renal Transplantation Threshold in Patients With Hepatitis C Liver Fibrosis and Cirrhosis: A Decision Analysis Model Gina Choi, Kristina Lee, Crystal Wu, Sammy Saab Background:Hepatitis C (HCV) infection is highly prevalent in patients with chronic kidney disease. There are no standard guidelines for the permissible degree of liver fibrosis prohibiting cadaveric renal transplantation (CRT). Our hypothesis is that patients with stage (S) 3 liver fibrosis who undergo CRT have improved survival at 5 years as compared to those remaining on HD. We hypothesize that S3 liver fibrosis alone should not prohibit HD patients from undergoing CRT who meet criteria given the survival benefit. Methods.Patients were stratified by METAVIR fibrosis score: S1, S2, S3, and S4. A decision analysis model was constructed to compare three strategies to determine survival at 5 years in patients with HCV-induced fibrosis on HD. In Strategy 1, chronic HCV patients remained on HD. In Strategy 2, chronic HCV patients remained on HD or underwent CRT. In Strategy 3, all patients were first treated with interferon monotherapy and then either remained on HD or underwent CRT. Progression of disease was accounted for in all three strategies. The probabilities of survival, progression of liver fibrosis, CRT, and sustained viral response (SVR) were obtained from a systematic review of the literature. Multiple one-way sensitivity analyses were performed. Results: Compared to strategy 1, strategy 2 and 3 improved overall 5-year survival: for S1 fibrosis, strategy 2 and 3 improved 5-year survival by 8.4 and 6.8%, respectively; for S2 fibrosis, strategy 2 and 3 improved 5-year survival by 8.6 and 9.3%, respectively; for S3 fibrosis, strategy 2 and 3 improved 5-year survival by 9.3 and 16.2%, respectively. 5-year survival was greater than 50% in all 3 strategies for patients with S1, S2, and S3 fibrosis. For patients with S4 fibrosis, 5-year survival was less than 50% for all 3 strategies (strategy 1: 29.3%, strategy 2: 30.4%, strategy 3: 31.9%). There was no benefit in treating S1 and S2 fibrosis patients with interferon monotherapy prior to CRT: overall 5-year survival in strategy 2 was 77.7% for S1 and 74.7% for S2, and in strategy 3, 76.1% for S1 and 75.4% for S2. One-way sensitivity analyses varying the probabilities of survival, progression of fibrosis, CRT, and SVR showed that the results were robust to the sensitivity analysis, with the exception of varying the probability of survival. Conclusion: Our model shows that CRT in patients with HCV-induced S1, S2, and S3 fibrosis improves overall 5-year survival. There is no benefit in overall 5-year survival in patients with S4 fibrosis and thus should not be candidates for CRT. There appears to be no overall 5-year survival benefit in treating S1 and S2 fibrosis patients with interferon monotherapy prior to CRT. Su1032 Effect of Glycemic Control on Survival Among Diabetic Veterans With Hepatitis C: A Retrospective Cohort Study With Twelve Years of Follow Up Meira Abramowitz, Elliot Bigajer, Rafayat Hossain, Mark M. Pinkhasov, Samy McFarlane, Ayse Aytaman Background: Hepatitis C (HCV) and type 2 diabetes mellitus (DM) are major causes of morbidity and mortality worldwide. It is widely recognized that chronic HCV is associated with insulin resistance and DM with substantial increase in cardiovascular risk. Previous work by our group indicated that the combination of HCV and DM among US veterans is associated with significantly decreased survival, compared with either disease alone or control group. The aim of this study is to examine the effect of hyperglycemia as a mediator of decreased survival among patients with DM and those with DM and HCV combined. Methods: Retrospective cohort study from the VA of the New York Harbor Healthcare System in Brooklyn, New York was conducted from an outcomes data base created between 2002- 2003. Patients with viremic HCV infection were selected from the HCV registry. These patients were compared to a computer generated random sample of patients treated in the VA primary care clinics. Information regarding patients' HCV and DM status was collected in the years 2002-2003, hemoglobin A1C (HgA1C) data was collected between the years of 2002-2013, and the mortality data was collected in the year 2013. Comparison between the groups was performed using descriptive statistics and Cox regression analysis to assess survival among different groups. Results: Among the 1,118 charts reviewed, 297 patients had DM only without HCV (DM only), and 142 patients had both DM and HCV (DM/HCV) (Table 1). The mean age for patients with DM only was 76.9. These patients were significantly older than patients with DM/HCV (64.0, p=0.002). The mean HgA1C for patients in the DM/HCV group was 7.6±0.18 which was significantly higher than the mean HgA1C for patients in the DM only group (7.1±0.08, p=0.001). After adjusting for age, there was a significant increase in mortality by 38% among patients in the DM/HCV group when compared to those in the DM only group (p=0.006). Using Cox regression analysis, we also examined the effect of hyperglycemia on survival in patients with DM only and with DM/ HCV. There was no significant effect for hyperglycemia on survival in patients with DM AASLD Abstracts